August 25, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
FDA approves Ziihera combinations for gastroesophageal adenocarcinoma
The FDA approved two zanidatamab-hrii-based regimens as first-line treatment for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma. Zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals) received approval in combination with fluoropyrimidine- and platinum-containing chemotherapy, and in combination with both fluoropyrimidine- and
811 words~4 min read
